Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

The most impactful AI products of 2026 aren't built to do everything; they're built to solve one problem exceptionally well. The ET Most In...

Rising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...

On Thursday evening, US President Trump said he would “hit Iran hard tonight”. Then, as the world waited with bated breath, came the announ...

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...

There are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

The government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...

Cancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...

India has a structural advantage in quantum computing. Its size inherently creates challenging optimisation issues, offering a practical te...

India is ready to welcome high-quality global pharmaceutical products. This move is in exchange for better market access for Indian drug ex...

Even in normal times it is futile to try and guess the outcome of most global events. But in the New World Order, it makes no sense at all ...

India's drug regulator, CDSCO, has mandated all drug companies to establish systems for tracking adverse drug reactions. This move comes am...

For the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...

Indian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...